Carl M. Mendel

TB Alliance — United States

Medicine · Health Sciences

41h-index8.2kcitations111works4.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tuberculosis Research and Epidemiology(32), Mycobacterium research and diagnosis(19), Hormonal and reproductive studies(12), Pneumonia and Respiratory Infections(8), Pharmacology and Obesity Treatment(8)

Publications111 total

Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant Tuberculosis
The Journal of Infectious Diseases·2025· 4 citedOpen Access
Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis
New England Journal of Medicine·2022· 511 citedOpen Access
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
The International Journal of Tuberculosis and Lung Disease·2021· 30 citedOpen Access
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
The International Journal of Tuberculosis and Lung Disease·2021· 61 citedOpen Access
An Exposure-Response Perspective on the Clinical Dose of Pretomanid
Antimicrobial Agents and Chemotherapy·2020· 10 citedOpen Access
Reply to Kim et al., “Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment”
Antimicrobial Agents and Chemotherapy·2020Open Access
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
New England Journal of Medicine·2020· 964 citedOpen Access
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
Antimicrobial Agents and Chemotherapy·2020· 38 citedOpen Access
A Partially-Randomised Phase 3 Trial of Pretomanid, Moxifloxacin and Pyrazinamide in Combination for the Treatment of Drug-Susceptible and Drug-Resistant Pulmonary Tuberculosis
SSRN Electronic Journal·2020· 1 citedOpen Access
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
The Lancet Respiratory Medicine·2019· 143 citedOpen Access
Daily Dosing for Bedaquiline in Patients with Tuberculosis
Antimicrobial Agents and Chemotherapy·2019· 30 citedOpen Access
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status
BMC Pulmonary Medicine·2019· 3 citedOpen Access
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis
Antimicrobial Agents and Chemotherapy·2019· 33 citedOpen Access
Measuring the Early Impact on Transmission of New Treatment Regimens for Drug Resistant Tuberculosis
2019· 5 cited
Late-Stage Clinical Programs 2018
Figshare·2019Open Access
Pretomanid susceptibility testing of Mycobacterium tuberculosis complex isolates using the BACTECTM MGITTM 960 system
The International Journal of Tuberculosis and Lung Disease·2019
Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study
BMC Medicine·2018· 37 citedOpen Access
Toxicity associated with tuberculosis chemotherapy in the REMoxTB study
BMC Infectious Diseases·2018· 37 citedOpen Access
Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis
BMC Medicine·2018· 80 citedOpen Access
Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study
BMC Medicine·2018· 73 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Angela M. Crook(10), Rodney Dawson(10), Melvin Spigelman(9), Daniel E. Everitt(8), Timothy D. McHugh(8), Stephen H. Gillespie(7), Andrew Nunn(7), Andreas H. Diacon(7), Ralph R. Cavalieri(7), Genevieve H. Wills(6), Patrick Phillips(5), Conor Tweed(5), Divan A. Burger(5), John P. Kane(5), Francesca Conradie(4), Andreas H. Diacon(4), Christo van Niekerk(4), Sarah Meredith(4), Stephen R. Murray(4), Ebrahim Variava(4)